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High-intensity focused ultrasound for noninvasive functional
neurosurgery
Abstract
Transcranial magnetic resonance (MR)-guided high-intensity focused ultrasound (tcMRgHIFU) implies
a novel, noninvasive treatment strategy for various brain diseases. Nine patients with chronic
neuropathic pain were treated with selective medial thalamotomies. Precisely located thermal ablations
of 4mm in diameter were produced at peak temperatures of 51 degrees C to 60 degrees C under
continuous visual MR guidance and MR thermometry. The resulting lesions are clearly visible on
follow-up MR imaging. All treatments were well tolerated, without side effects or neurological deficits.
This is the first report on successful clinical application of tcMRgHIFU in functional brain disorders,
portraying it as safe and reliable for noninvasive neurosurgical interventions.
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Abstract Transcranial magnetic resonance guided high intensity focused 
ultrasound implies a novel, non-invasive treatment strategy for 
various brain diseases.  
Nine patients with chronic neuropathic pain were treated with 
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selective medial thalamotomies. Precisely located thermal 
ablations of 4mm diameter were produced at peak temperatures of 
53°C to 60°C under continuous visual MR-guidance and MR-
therm ometr y. T he res ulting lesions are clearly visible on follow-up 
MRI. All treatments were well tolerated, without s ide effects or 
neurological defic its. This is the firs t report on s ucc essful c linic al 
application of transcranial magnetic resonance guided high 
intensity focused ultrasound, portraying it as safe and reliable for 
non-invasive neurosurgical interventions 
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Introduction 
For over 50 years researchers have been seeking for a way to perform non-invasive 
thermal ablation for brain treatments1, 2. Recent technical advances have made 
Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) a firmly 
established modality for non-invasive surgery under closed loop image guidance and 
control throughout all steps of the intervention process3-5. MR-imaging allows for 
precise intraprocedural localization of the ablation target6, definition and verification 
of safety margins for the ultrasound treatment, real-time monitoring of thermal 
ablation dynamics7, and intra- and post-treatment assessment of intervention results. 
Thanks to its non-invasiveness MRgHIFU minimizes the risk of bleeding and infection 
and avoids collateral damage to non-targeted tissue8. In addition, it does not involve 
ionizing radiation. Transcranial application of MRgHIFU, therefore, promises to 
become an important new modality for neurosurgical interventions9, 10 and is 
envisioned to enable novel treatment strategies against a variety of brain diseases5, 
11-13
. 
Based on our long-term clinical experience in functional neurosurgery of neuropathic 
pain with stereotactic interventions in the medial thalamus14-16, we developed 
intervention processes to access ablation targets in the brain non-invasively, using 
transcranial MRgHIFU (tcMRgHIFU). Following preclinical studies with phantoms, 
biological tissues and human ex-vivo head preparations, a clinical phase I study was 
initiated to investigate the feasibility, reproducibility, accuracy and safety of 
tcMRgHIFU for functional neurosurgery. The study was approved by the ethics 
committee of the University and the State of Zurich. 
 
Patients and Methods 
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Patients 
Having obtained fully informed written consent nine patients scheduled for a selective 
central lateral thalamotomy (CLT)16 against chronic therapy-resistant neuropathic 
pain were enrolled. Therapy-resistance was established by lack of efficiency of anti-
epileptic and anti-depressant drugs. The first nine interventions encompassed 
patients aged 45 to 75 years suffering from pain in the face (3 patients), neck (1 
patient), lower extremity (2 patients), upper extremity (2 patients) and hemibody (1 
patient), of central (3 patients) or peripheral (6 patients) origin. The 9 causal lesions 
at the origin of the different neuropathic pain syndromes were amputation, nerve 
compression by disc prolapse or neurinoma, zoster infection, nerve trauma, brachial 
plexus avulsion and thalamic infarct. One additional patient suffered from idiopathic 
trigeminal neuralgia, and another from a neuropathic pain syndrome in the context of 
cervical dystonia. The duration of pain in these patients was between 1.5 and 17 
years (mean: 7.5 years).  
 
Surgery and Intraoperative Observations 
The non-invasive neurosurgical interventions were performed in a clinical 3Tesla MR-
system (Signa HDx, GE, Milwaukee, USA) using a clinical system for tcMRgHIFU 
surgery (ExAblate 4000, InSightec, Tirat Carmel, Israel) featuring a hemispheric 1024 
element phased array transducer operating at 650kHz. 
The fully shaved patient’s head was immobilized within a MR-compatible frame 
(Radionics, Burlington USA) and carefully positioned in the helmet-like cavity of the 
ultrasound transducer (Fig 1). The space between transducer and head surface was 
sealed with a flexible membrane and filled with degassed water for ultrasound 
coupling. The water was circulating at 16°C for continuous scalp cooling. The 
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ablation target, i.e. the posterior part of the thalamic central lateral nucleus, was 
localized on 3D T1-weighted MR-images using the multiarchitectonic Morel atlas of 
the human thalamus and basal ganglia17. The coordinates of the sonication lesions 
were determined and entered into the planning software of the MRgHIFU system. 
Intrinsically, tcMRgHIFU sonications are not limited by trajectory restrictions and offer 
several degrees of freedom to taylor the sonication pattern for optimal target volume 
coverage: peak temperature, sonication duration and combination of multiple 
sonication lesions.  
Before the actual treatment phase of the tcMRgHIFU intervention it was confirmed 
that the thermal hot spot was centered in the target location. For this, several low 
power sonications of 10s to 20s duration were applied to induce peak temperatures 
of 39°C to 42°C. These temperatures are known to be below the ablation threshold 
but are easily visualized on MR-thermometry images to assess exact position and 
size of the hotspot and the overall safety profile of the applied sonication 
parameters18 (Fig 2A). 
During treatment several high power sonications were applied in an iterative process 
guided by MR-imaging and MR-thermometry. In order to induce local tissue ablation 
the acoustic power was stepwise increased from sonication to sonication to finally 
achieve a peak temperature at the target between 53°C and 60°C (Fig 2B). Typically, 
continuous wave sonications of 10s to 20s duration up to a maximum acoustic power 
of 1,200W and 800W, respectively, corresponding to 12,000J per sonication were 
applied. 
Patients were fully awake and responsive during all stages of the intervention. The 
only medication administered before the procedure comprised an oral 
Benzodiazepine. In two cases a subcutaneous opiate injection was necessary 
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because of back pain due to lying motionless supine on the MR-table for an extended 
period of time. During the entire series of sonications, patients were monitored and 
questioned repeatedly to ensure their neurological integrity and to assess changes in 
pain quality, extension and intensity or other sensations experienced during the 
treatment. 
 
Results 
Selective CLT against chronic neuropathic pain have been applied in nine patients 
using the novel, non-invasive tcMRgHIFU technology. Patients were monitored 
continuously before, during and after each sonication period, were asked for their 
subjective experience (pain reduction, somatosensory improvements, vestibular 
feelings, par- and dysesthesias), and were examined to exclude any motor or 
somatosensory deficit. All treatments were well tolerated and no side effects or 
neurological deficits were observed. Operating at peak temperatures of 53°C to 60°C 
(except in the very first patient, where the peak temperatures were kept below 50°C 
for safety reasons) under closed-loop MR-guidance, precisely located lesions of 3mm 
to 5mm diameter were evident in 48h-postop MR-imaging. Pain relief two days after 
the interventions ranged from 30% to 100% (mean: 68%). Patients reported 
sonication effects during the procedure, such as pain relief (9 patients), 
somatosensory improvements (5 patients), vestibular feelings (5 patients), 
paresthesias (3 patients) or dysesthesias (7 patients) in and around the pain area. 
These symptoms were observed in some patients already at focal temperature below 
50°C. 
MR-imaging of the sonication lesions immediately following the intervention (in two 
patients) and 48h after the intervention (in all nine patients) revealed three concentric 
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zones on T2-weighted images (T2WI). They consist of a somewhat heterogeneous 
iso- to hypointense center (zone I) surrounded by a strongly hyperintense region 
(zone II). Zone II is sharply demarcated by a small hypointense rim towards an outer 
slightly fuzzy and irregularly shaped area (zone III) of lower hyperintensity (Fig 3A 
and 3B). This corresponds well to earlier studies on animal brains6, 8. The irregularly 
bordered outer zone III extends up to a maximum diameter of 10 to 12mm at 48h 
post intervention and represents the perifocal edema. It is best seen as diffusely 
hyperintense area on T2WI (Fig 3A and 3B). 
Depending on the peak temperature achieved, the size of zone I immediately 
following the intervention and 48h postoperatively is 1 to 2mm in diameter on axial 
planes and 2 to 3mm in length on sagittal and coronal slices. The hyperintense zone 
II has a diameter of 3 to 4mm and a length of 4 to 5mm. These inner two zones I & II 
correspond most probably to the areas of coagulated and necrotic tissue8 and are 
immediately and 48h postoperatively strongly hyperintense on isotropic diffusion 
images (Fig 3E and 3F), indicative of coagulation necrosis and cytotoxic edema. 
They are slightly hypointense on apparent diffusion coefficient maps and on T1WI, 
with a strong ring-enhancement of about 1 to 2mm thickness after administration of 
an intravenous contrast agent immediately after the intervention (Fig 3C), but almost 
no longer apparent at 48h follow-up (Fig 3D). 
Previous reports based on in-vivo data in rabbit brain show that a thermal dose 
equivalent of 17min at 43°C (17 CEM 43°C) will result in 50% tissue damage19. In 
accordance with these findings, the total size of zone I & II as seen on T2WI (Fig 3A 
and 3B) after treatment matches exactly the area that accumulated more than 17 
CEM 43°C on MR-thermometry images during treatment (Fig 2C). 
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The precision of tcMRgHIFU targeting was calculated by comparing the centers of 
the zone II on T2WI 48 h postoperatively and presurgical stereotactic coordinates of 
the ablation targets. So far, for nine targets in five patients the median / mean ± 
standard deviation are: dorso-ventral 0.5 / 0.61 ± 0.56mm ; (ii) antero-posterior 1.5 / 
1.16 ± 0.57mm; (iii) medio-lateral 0.5 / 0.96 ± 0.87mm. 
 
Discussion 
The preliminary findings of our ongoing clinical phase I study on nine patients 
indicate that tcMRgHIFU is a safe, reliable and precise modality for non-invasive 
neurosurgical interventions for the first time and highlight the potential of this novel 
technology. All treatments could be safely performed and successfully executed to 
the planned endpoints owing to closed-loop high-field MR-image guidance. The 
sonication protocol allows for optimal target coverage: (i) by applying multiple 
sonication lesions, and (ii) by freely choosing the position of the sonication lesions 
without trajectory restrictions. Being non-invasive, all treatments were performed on 
fully awak e patients as an outpatient proc edure. Although pain reli ef was imm ediate 
in all treated patients, prior studies of thalamotom y have sugges ted that such relief 
might be transient. Our previous res ults with radiof requenc y CLT on a large series of 
pati ents 16 dem ons trate long term (m ean follow-up 3 years 9 m onths) pain relief 
between 50% and 100% in 53% of patients . Follow-up MRI s tudies (as im plem ented 
here), physiological tests (quantitative EEG with spectral analysis and source 
localization), as well as clinical examinations (pain questionnaire, visual analog scale 
and neurological examination by independent observer) are planned at 3 and 12 
months postoperatively to document in detail the long term post-sonication evolution 
of the patients. 
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Figure Captions: 
Fig 1. Patient prepared for transcranial MRgHIFU intervention. 
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The head is immobilized within a stereotactic frame. The transducer is positioned 
using a 3-axis mechanical positioner. The flexible membrane seals the space 
between patient head and transducer, which is filled with degassed water. The bore 
of the 3T MR-scanner is visible in the background.  
Fig 2. MR-image guidance of transcranial MRgHIFU intervention. 
(A) Thermal map on axial plane at the level of the third ventricle. Thermal maps are 
refreshed at intervals of 3 to 5s to monitor localization and dynamics of temperature 
rise during sonication and subsequent temperature relaxation during cooling period. 
The blue circle delineates the planned sonication target in the posterior part of the 
central lateral thalamic nucleus. The red cross marks the pixel with the highest 
temperature at the end of sonication. The three wedge shaped forms are placed by 
the operator to balance background noise in thermal calculations. (B) Red: 
temperature evolution during a therapeutic sonication of 12s duration using 850W in 
the voxel of highest temperature. Time resolution 4s, monitored cooling period 
aftersonication 30s. Green: temperature evolution of average temperature of the 
neighbouring voxels around the temperature maximum. (C) Red circle: Contour line 
of thermal dose corresponding to 17 CEM 43 C (see text) at the target location 
superimposed on the T2 weighted MR image (T2WI) obtained 48h after treatment. 
(D) Stereotactic reconstruction of MRgHIFU-guided CLT. The outline of the lesion 
(dotted circle) corresponds to the extent of zone II (3 to 5mm diameter) seen on axial 
T2WI taken 48h postoperatively. The location of the CLT is determined by projecting 
the corresponding atlas map (6.3mm dorsal to intercommissural plane) onto the 
T2WI using the position of the posterior commissure (black cross) for anteroposterior 
alignment. Scale bars = 4mm. For abbreviations see reference 17. 
Fig 3. Post treatment MR-images.  
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(A), (C), (E) Axial T2WI, post contrast T1WI and isotropic diffusion tensor image, 
respectively, of patient #2, obtained immediately after treatment with transcranial 
MRgHIFU. Two sonication lesions of 3-5mm diameter were placed into the right 
posterior part of the central lateral nucleus of the thalamus (for image description see 
text). 
(B), (D), (F) Axial T2WI, post contrast T1WI and isotropic diffusion tensor image, 
respectively, of patient #3, obtained 48h after treatment with transcranial MRgHIFU. 
One sonication lesion was placed bilaterally in each of the posterior parts of the 
central lateral thalamic nuclei (for image description see text).  
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